<DOC>
	<DOCNO>NCT00630435</DOCNO>
	<brief_summary>The purpose trial determine equivalence 3 new formulation Premarin速/medroxyprogesterone acetate ( MPA ) combination tablet currently market dosage form ( Prempro速 [ TM ] ) . This study perform healthy postmenopausal woman . Each subject participate study approximately 14 week , include screen evaluation within 3 week study , four , 6-day , 5-night inpatient period least 21-day washout interval dose administration .</brief_summary>
	<brief_title>Study Comparing 3 New Formulations Premarin速 0.625 mg/MPA 2.5 mg With Reference Formulation</brief_title>
	<detailed_description />
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<criteria>Inclusion 1 . Healthy postmenopausal woman age 35 70 . 2 . Body mass index 18 35 kg/m2 , weight must least 50 kg . 3 . Nonsmoker smoker few 10 cigarettes/day . Exclusion 1 . History presence hypertension ( &gt; 139 mm Hg systolic &gt; 89 mm Hg diastolic ) . Can take 2 antihypertensive medication keep blood pressure control . 2 . History within 1 year study day 1 alcohol drug abuse . 3 . Use investigational drug within 30 day study day 1 .</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Premarin速</keyword>
</DOC>